OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

February 19th 2015

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Bob Asinof on Recruiting Physicians to Private Centers

February 18th 2015

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Dr. Matthew Davids On Advances in CLL

February 18th 2015

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations

February 18th 2015

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17th 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

February 16th 2015

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

February 13th 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

February 10th 2015

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

February 10th 2015

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

Dr. Jia Ruan on Mantle Cell Lymphoma Treatment Challenges

February 9th 2015

Jia Ruan, MD, PhD, an associate professor at Weill Cornell Medical College, talks about initial treatment methods for mantle cell lymphoma (MCL).

Dr. Mark Delworth on Robotic Prostatectomy

February 9th 2015

Mark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.

Dr. Ian Flinn on the Changing Treatment Paradigm for CLL and Low-Grade Lymphoma

February 6th 2015

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses how the approvals of idelalisib and ibrutinib will change treatment paradigms for chronic lymphocytic leukemia (CLL) and low-grade lymphoma.

Dr. Gertz on Expanding Treatment Options for Myeloma

February 6th 2015

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

February 5th 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

February 4th 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer

February 3rd 2015

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

Dr. Taneja on MRI for Prostate Cancer Detection

January 30th 2015

Samir Taneja, MD, professor of Urology and Radiology and director of the Division of Urologic Oncology at NYU Langone Medical Center.

Dr. Brentjens on CAR T-Cell Therapy Challenges

January 30th 2015

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.

NEXT PAGE
PREVIOUS PAGE